Philippe Moreau, MD

Dr Moreau highlights key findings on MRD negativity dynamics from IMROZ and their future implications for patients with newly diagnosed multiple myeloma.

Dr. Philippe Moreau presents analyses of minimal residual disease (MRD) negativity dynamics from the Phase 3 IMROZ study, highlighting the sustained depth of response, progression-free survival benefits, and reduced MRD relapse rates with isatuximab plus VRd in transplant-ineligible patients with newly diagnosed multiple myeloma.

Philippe Moreau, MD, discusses the FDA approval of isatuximab-irfc plus carfilzomib and dexamethasone in relapsed/refractory multiple myeloma.

Philippe Moreau, MD, head of the Hematology Department, University Hospital of Nantes, France, discusses the combination treatments being used to treat patients with multiple myeloma.

Philippe Moreau, MD, head of Department of Hematology, Centre Hospitalier et Universitaire, Nantes, France, discusses the phase III Tourmaline-MM1 study for patients with relapsed/refractory multiple myeloma.